The British Association for Psychopharmacology [BAP], as they do every year, is inviting sponsorship for its Summer Meeting. Here are the packages of “available opportunities” for the 2026 BAP Summer Meeting:
In the supporting material for these commercial opportunities, BAP sets out requirements to “align” with BAPs Policy on Relations with Industry:
What is not made clear is that a significant number of those who give educational lectures at BAP Summer Meetings are career-long paid opinion leaders and that there is no means of establishing how much they have been paid over their careers by Industry [the UK has no Sunshine legislation to make full declarations of financial payments mandatory].
Professor Stephen Stahl, who gave an “Expert Seminar” at the 2015 BAP Summer Meeting is an American psychiatrist. Sunshine legislation has been in place in the USA for over the last decade. In the 18 months before giving his “Expert Seminar” at this BAP Summer Meeting, Professor Stahl had been paid over £3.5 million by pharmaceutical companies marketing psychiatric drugs.
BAP, states beside the “available opportunities” it offers for Industry at the BAP 2026 Summer Meeting:
This assurance cannot be taken at face-value. Here is evidence of a Decade of Summer Meetings that reveals that this casual reassurance does not reflect reality: